NTHI
NASDAQ · Pharmaceuticals
Neonc Technologies Holdings
$7.88
+0.57 (+7.80%)
Financial Highlights (FY 2026)
Revenue
96.2K
Net Income
-13,873,756
Gross Margin
100.0%
Profit Margin
-14,335.5%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 65.6% | 65.6% | 65.6% |
| Operating Margin | -11,099.3% | 28.2% | 28.5% | 22.9% |
| Profit Margin | -14,335.5% | 20.8% | 18.7% | 18.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 96.2K | 43.67M | 45.52M | 48.53M |
| Gross Profit | 96.2K | 28.64M | 29.85M | 31.83M |
| Operating Income | -10,675,123 | 12.31M | 12.96M | 11.13M |
| Net Income | -13,873,756 | 9.08M | 8.50M | 8.83M |
| Gross Margin | 100.0% | 65.6% | 65.6% | 65.6% |
| Operating Margin | -11,099.3% | 28.2% | 28.5% | 22.9% |
| Profit Margin | -14,335.5% | 20.8% | 18.7% | 18.2% |
| Rev Growth | — | -7.1% | -1.4% | +12.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | — | 13.21M | 13.53M | 15.66M |
| Total Equity | — | 166.04M | 174.37M | 161.35M |
| D/E Ratio | — | 0.08 | 0.08 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -10,455,046 | 14.45M | 13.90M | 17.76M |
| Free Cash Flow | — | 12.29M | 13.27M | 13.39M |